All Episodes

Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

David Kavanagh, MBChB, PhD, FRCP - A Clinically Considered Real-World Case Series: Practice Essentials From Biopsy To Diagnosis in Immune-Mediated Glomerular Diseases

Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?

Yohei Doi, MD, PhD - Know the Risk, Act on Evidence: Strategic Interventions in COVID-19 Care of High-Risk Patients

Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring?

Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: Breaking Down the Data Driving Therapeutic Developments in IgA Nephropathy

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: A Fresh Look at the Data Driving Targeted Therapeutic Developments in IgA Nephropathy

David Alain Wohl, MD - Inpatient Management of SARS-CoV-2 Infection: Applying Learnings From Real World Evidence to Real World Practice

Nancy Carteron, MD, FACR - Congress Insights Direct From Chicago: The Need-to-Knows on B Cell–Targeting in Sjögren’s Disease

Emer Joyce, MB BCh BAO, PhD - Staying Ahead of the Curve in ATTR-CM: Adapting and Advancing Our Approach to Decision-Making as the Treatment Landscape Evolves

Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care

Jonathan Barratt, PhD, FRCP - Preserve and Prevent: Expert Perspectives on Optimizing Outcomes in Patients With IgAN

Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC

Amber S. Podoll, MD, FASN - Stepping Up Kidney Protection in Patients With Lupus Nephritis: When and How?

Jonathan Barratt, PhD, FRCP - The Gut–Kidney Axis and Beyond in IgA Nephropathy: A New Frontier in Precision Therapy

Alberto Ortiz, MD, PhD - Rare, Complex, and Life-Threatening: Recognizing and Responding to Atypical Hemolytic Uremic Syndrome

Thanai Pongdee, MD - From Diagnosis to Treatment Escalation: Improving Outcomes Across the Patient Journey in Indolent Systemic Mastocytosis

Jonathan Barratt, PhD, FRCP - The Nephrology Journal Club: B-Cell Modulators and eGFR Endpoints in IgA Nephropathy

Neal Shore, MD, FACS - Redefining Expectations in mHSPC: Options and Opportunities Across the Spectrum of Disease

Howard Trachtman, MD - Pioneering Progress In Focal Segmental Glomerulosclerosis: Time is Ticking To Save The Nephron

Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?

Lorenza Rimassa, MD - Shifting the Paradigm in Biliary Tract Cancers: Contemporary Data and Decision-Making

Diana L. Bitner, MD, MSCP, FACOG - Let’s Replace Silence With Science: Patient and Provider Perspectives on Addressing the Substantial Impact of Menopausal Symptoms

Liz Lightstone, MBBS (Hons), PhD, FRCP - Preventing Flare and Protecting Function: What Progress Is Being Made in Active Lupus Nephritis?

Anna Maria Geretti, MD, PhD - Understanding an Individual’s Readiness for Long-Acting Injectable Therapy

Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed

Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)

Mariana Castells, MD, PhD - Rare But Highly Significant: Best Practices in Recognizing and Diagnosing Systemic Mastocytosis

Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC

Kris V. Kowdley, MD - Prioritising the Patient Experience With PBC: Are We Appreciating and Addressing the True Impact of the Disease?

Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Cancer

Onyema Ogbuagu, MD, FACP, FIDSA - Multidrug-Resistant HIV: Evaluating HIV Treatment Strategies as Options Narrow

Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours

Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML

Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice

Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals

Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences

Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates

Karin Jordan, MD, PhD - Practical Protocols for Preventing and Managing Antibody-Drug Conjugate-Associated Nausea and Vomiting

Frank Siebenhaar, PD / Vito Sabato, MD, PhD - Optimising Outcomes in Indolent Systemic Mastocytosis: A Comprehensive Review of Best Practices Across the Patient Journey

Sharon Walmsley, MD - If the Drugs Are Working, Why Switch HIV Treatment in People Who Are Virologically Suppressed?

Jane Anderson, FRCP, PhD - Health-Related Quality of Life: What Works Best for People Living With HIV?

Jai Radhakrishnan, MD, MS, Getting Up to Speed in IgAN: An Expert-Led Rapid-Fire Journal Club Series

Philippe Moreau, MD - Assessing Current and Potential Approaches in Multiple Myeloma: Updates From Madrid 2024

Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy

David Malka, MD, PhD - Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey

Xenofon Baraliakos, MD, PhD / Philip Helliwell, MD, PhD - Can the Standard of Care Be Elevated in Spondyloarthropathies? Key Learnings From Rheumacensus Initiatives in PsA and axSpA

Milan J. Anadkat, MD - Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communications Strategies to Improve Shared Decision-Making

Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents

Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?

Bertrand Tombal, MD, PhD - MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optimise Outcomes

Wisia Wedzicha, MD, FRCP - Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care

David M. G. Halpin, MB BS, DPhil, FERS - The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of Disability and Death

Ana C. Garrido-Castro, MD / Sarah L. Sammons, MD - TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Significance of the Construct

Brian I. Rini, MD, FASCO - Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in Renal Cell Carcinoma

Lorenza Rimassa, MD - When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising Treatment Planning in Cholangiocarcinoma

Jürgen Rockstroh, MD - HIV and Hepatitis B: Managing Coinfections in PLWH

Antonella Castagna, MD - Designing Treatment Regimens to Suppress Multidrug-Resistant HIV: What Would You Do?

Frank Siebenhaar, MD - Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms

David Malka, MD, PhD - Let’s Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma

Jai Radhakrishnan, MD, MS / Ladan Zand, MD - Investigating Novel Approaches and Unmet Needs in the Management of Glomerular Diseases

Javier Cortés, MD, PhD - Updates on HER3-Targeted Therapies in NSCLC and Breast Cancer

Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations

Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses

Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations

Julia Rotow, MD / Javier Cortés, MD - HER3-Targeted Therapies: How Might These Benefit Our Patients?

Stefano Fanti, MD - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses

Nizar Mahlaoui, MD, MPH, PhD - Simplifying Patient-Integrated Care for Those Requiring Immunoglobulin Therapy: Making Smart Moves with Automated and Digital Technology

Kevin Harrington, PhD, FRCR, FRCP - When CPS is Between 1 and 19, How Would You Manage Recurrent/Metastatic SCCHN?

Thomas Powles, MBBS, MRCP, MD - Education, Collaboration and Communication: Aligning Patient and Clinical Priorities in Locally Advanced and Metastatic Urothelial Carcinoma

Arndt Vogel, MD - Mobilising the Multidisciplinary Team: Collaborative Strategies to Improve Care in Early- to Intermediate-Stage HCC

Andrew Ustianowski, MBBS, FRCP, PhD - Treating COVID-19 Early: What Patients Need to Know

Marina Berenguer, MD, PhD - Treating Hepatitis C Virus in Special Populations: Pregnant Women, Children and Adolescents

Andrew Ustianowski, MBBS, FRCP, PhD - What’s Right for Me: Individualising Antiretroviral Therapy in People Living With HIV

Amitava Banerjee, MPH, DPhil, FRCP - Long COVID and Vaccination Status: What Are We Learning?

Anil K. Gupta, MD, CCFP, FCFP - Treating COVID-19 in the Outpatient Setting: Identifying Who, With What, and When?

Solange Peters, MD, PhD - Advancing Our Patient-Centered Approach to Care in ALK-Positive Metastatic Non-Small Cell Lung Cancer

Franco Cecchi, MD - Improving Collaborative Care for HCM: Tips and Tricks From the Multidisciplinary Cardiology Team

Robert L. Coleman, MD - New Horizons in Cervical Cancer: Spotlight on Antibody-Drug Conjugates

Ronald van Vollenhoven, MD, PhD - Managing Patients with Lupus: When Should We Escalate Treatment?

Frederique Penault-Llorca, MD, PhD - Setting Our Sights on Actionable Mutations in Cholangiocarcinoma: The Who, What, When, Why, and How of Testing

Perry Elliott, MD, FRCP, FESC - Thickening of the Heart, and HCM Is to Blame: A Call for Improved Recognition, Diagnosis, and Management of HCM

Susana Banerjee, MBBS, MA, PhD - When Patients With Advanced Endometrial Cancer Progress: Decisions in Treatment Initiation and Optimisation

Anil K. Gupta, MD, CCFP, FCFP / Nathan Peiffer-Smadja, MD, PhD - Steps Towards Preventing COVID-19 Variants: Because Every Individual Counts

Ewa A. Jankowska, MD, PhD - Breakthroughs and Game-Changers in Heart Failure

Kjeld Schmiegelow, MD, DMSci - Asparaginase Therapy in Children and Young Adults With ALL/LBL: When You Need to Switch

Luke Stephen Prockter Moore, FRCP, FRCPath, PhD - A Cohesive Multidisciplinary Approach to Antimicrobial Stewardship: Joining the Dots on Rapid Diagnostic Testing

Anton Pozniak, MD, FRCP - Resistance is Futile: Achieving and Maintaining HIV Viral Suppression

Paolo Antonio Ascierto, MD - Emerging Data on Adjuvant Immunotherapy for Resected Melanoma: What Changes?

Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered

José R. Arribas, MD - Mastering the Management of Multidrug-Resistant HIV: When, With What, and How

Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice

Ask, Spot, Refer: Identifying Acute Hepatic Porphyria in the Emergency Room

Managing Cytopenic Myelofibrosis: New and Emerging Therapies and Who May Benefit

Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC

Personalised Management of Newly Diagnosed Secondary Acute Myeloid Leukaemia: Determining Factors That Impact Treatment Decisions

Reassessing Management of Advanced and Recurrent Endometrial Cancer: The Value of Multidisciplinary and Overall Care

Question Time: Applying New Therapies for the Management of mTNBC

New Biomarkers, New Targets in Advanced NSCLC

Addressing the Triple Challenge of Myelofibrosis: Symptoms, Splenomegaly, and Cytopenias

Practical Guidance for Identifying and Managing Patients With Advanced MET Exon 14-Skipping NSCLC

Insights on the Increasing Impact of Emerging Therapies in NSCLC: Highlights From Spring 2022

Lupus and the Kidney: Emerging Treatment Strategies and How to Use Them

Evolving Clinical Management of the Hospitalised COVID-19 Patient

Managing the Nuances of Paroxysmal Nocturnal Haemoglobinuria: Practical Strategies for Patients Receiving Complement Inhibitors

Maintenance Therapy in COPD: Optimising Benefit With Inhalers When Ability to Inhale is Compromised

Managing Thrombosis in Cancer: A Double Debacle and Then Add COVID

Managing Complex Patients Hospitalized Due to COVID-19: Cases in Practice

The Patient’s Portrait When Selecting ART: Cases in Practice

Standards of Care in HIV: We’ve Come a Long Way, But Could We Achieve More?

A Clinical Conversation on Metastatic Hormone-Sensitive Prostate Cancer: Intensifying Therapy Earlier in the Disease Course

"Defining the Diagnosis and Management of Pyruvate Kinase Deficiency"

"Incorporating Immunotherapy in Advanced and Recurrent Endometrial Cancer: Applying Knowledge to Practice"

Individualising Enzyme Replacement Therapy in Patients Living with Late-Onset Pompe Disease

Pros and Cons of Colloid Treatment: Cases in the Critically Ill

Help, I Have COVID': Primary Care Support and Therapeutic Management of Patients With Mild/Moderate COVID-19

When the Immune System Attacks: The Impact, Pathophysiology, and Treatment of Alopecia Areata

Optimising Outcomes for Chronic Kidney Disease: The Emerging Treatment Paradigm